Rubius is developing a new class of drugs, Red-Cell Therapeutics™,
for the treatment of a wide array of diseases.

Our Story

Rubius was co-founded by Avak Kahvejian, Ph.D., Jordi Mata-Fink, Ph.D., Noubar Afeyan, Ph.D., all of Flagship VentureLabs®, the innovation foundry of Flagship. The academic co-founders are Harvey Lodish, Ph.D., and Hidde Ploegh, Ph.D., both of MIT and the Whitehead Institute for Biomedical Research.

VentureLabs has been creating breakthrough companies since 2000. It is the first institution dedicated to entrepreneurial innovation, where discovery, invention and entrepreneuring are performed simultaneously by a world-class team of scientists, innovators and professional entrepreneurs. VentureLabs innovates, invents, launches and builds startups through a unique, systematic approach that produces best-in-class companies based on in-house innovations. VentureLabs has started 35 life science and technology companies, including Joule Unlimited, Seres Therapeutics (NASDAQ: MCRB), Pronutria Biosciences, Symbiota and Moderna Therapeutics.